Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations

Abstract Background The efficacy of definite for non‐small‐cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations has been preliminarily demonstrated. However, there is a paucity of data with which to compare the efficacy and safety of second‐ and third‐generation T...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Yue Hao, Manyi Xu, Jianan Jin, Jinfei Si, Chunwei Xu, Zhengbo Song
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2023-08-01
Saila:	Cancer Medicine
Gaiak:	afatinib efficacy NSCLC osimertinib safety uncommon EGFR mutation
Sarrera elektronikoa:	https://doi.org/10.1002/cam4.6229
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!